Uterine Cervical Neoplasms
📧 Sign up to get email alerts when something new happens for Uterine Cervical Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
-
EMA approval · 2026-06-05EMA Authorised: Tivdak (tisotumab vedotin) — Genmab A/S
EMA authorised Tivdak (tisotumab vedotin) for uterine cervical neoplasms, expanding treatment options in this indication.
-
EMA approval · 2026-03-31EMA Authorised: Topotecan Hospira (topotecan) — Pfizer Europe MA EEIG
EMA authorised Topotecan Hospira for use in small cell lung cancer and uterine cervical neoplasms.
-
EMA approval · 2026-02-24EMA Authorised: Tivdak (tisotumab vedotin) — Genmab A/S
The European Medicines Agency authorised Tivdak (tisotumab vedotin) for uterine cervical neoplasms, with Genmab A/S as the marketing authori…